XLO vs. MCRB, BTMD, IOBT, MOLN, IMRX, GNLX, HURA, CTOR, CLYM, and ALTS
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Seres Therapeutics (MCRB), biote (BTMD), IO Biotech (IOBT), Molecular Partners (MOLN), Immuneering (IMRX), Genelux (GNLX), TuHURA Biosciences (HURA), Citius Oncology (CTOR), Climb Bio (CLYM), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry.
Xilio Therapeutics vs. Its Competitors
Xilio Therapeutics (NASDAQ:XLO) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.
Xilio Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 326.68%. Seres Therapeutics has a consensus target price of $73.67, indicating a potential upside of 278.94%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Xilio Therapeutics is more favorable than Seres Therapeutics.
Xilio Therapeutics has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.9, suggesting that its stock price is 190% more volatile than the S&P 500.
Seres Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -374.79%. Seres Therapeutics' return on equity of -350.16% beat Xilio Therapeutics' return on equity.
In the previous week, Xilio Therapeutics had 5 more articles in the media than Seres Therapeutics. MarketBeat recorded 6 mentions for Xilio Therapeutics and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.84 beat Xilio Therapeutics' score of -0.37 indicating that Seres Therapeutics is being referred to more favorably in the news media.
Seres Therapeutics has higher revenue and earnings than Xilio Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Xilio Therapeutics beats Seres Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:XLO) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access